Press Release Biocartis Group NV: Biocartis Announces Resignation CFO
Press Release Biocartis Group NV: Biocartis Announces Resignation CFO
PRESS RELEASE
新聞稿
REGULATED INFORMATION – INSIDE INFORMATION
5 June 2023, 17:40 CEST
受監管的資訊-內幕消息RM國家
2023年6月5日，中部夏令時間17：40
BIOCARTIS ANNOUNCES RESIGNATION CFO
Biocartis宣佈辭職首席財務官
Mechelen, Belgium, 5 June 2023 – Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that Jean-Marc Roelandt, the Company's Chief Financial Officer ('CFO')1, has decided to resign from Biocartis for personal reasons.
梅切倫，比利時，5. 六月2023.-創新型分子診斷公司Biocartis Group NV(以下簡稱“公司”或“Biocartis”)今天宣佈，公司首席財務官Jean-Marc Roelandt(“CFO”)1，因個人原因決定辭去Biocartis的職務。
Biocartis has initiated a selection process to recruit a new CFO. The Company and Mr. Roelandt have agreed that he will stay with Biocartis until 4 August 2023 to ensure a smooth transition for the Company.
Biocartis已經啟動了招聘新CFO的遴選程式。公司和Roelandt先生已同意他將在Biocartis工作到2023年8月4日，以確保公司的平穩過渡。
--- END ---
-完--
More information:
更多資訊：
Investor Relations Biocartis
e-mail ir@biocartis.com
tel +32 15 632 600
@Biocartis_
投資者關係Biocartis
電子郵件：ir@biocartis.com
電話：+32 15 632 600
@Biocartis_
About Biocartis
關於Biocartis
With its revolutionary and proprietary Idylla platform, Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing, by making molecular testing actionable, convenient, fast and suitable for any lab. The Idylla platform is a fully automated sample-to-result, real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster, informed treatment decisions. Idylla's continuously expanding menu of molecular diagnostic tests address key unmet clinical needs, with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today, Biocartis offers tests supporting melanoma, colorectal, lung and liver cancer, as well as for COVID-19, Flu, RSV and sepsis. For more information, visit or follow Biocartis on Twitter @Biocartis_ , Facebook or LinkedIn.
憑藉其革命性和專有的Idylla平臺，Biocartis(Euronext布魯塞爾股票代碼：BCART)致力於通過普遍獲得分子檢測，使分子檢測可操作、方便、快速並適用於任何實驗室，從而為世界各地的患者提供個性化藥物。Idylla平臺是一個完全自動化的從樣品到結果的實時聚合酵素鏈式反應(Polymerase Chain Reaction)系統，旨在提供內部訪問，在最短的時間內獲取準確的分子資訊，以便做出更快、知情的治療決定。Idylla不斷擴大的分子診斷測試菜單解決了關鍵的未得到滿足的臨床需求，重點是腫瘤學。這是全球分子診斷市場增長最快的細分市場。今天，Biocartis提供支持黑色素瘤、結直腸癌、肺癌和肝癌以及新冠肺炎、流感、呼吸道合胞病毒和膿毒症的檢測。欲瞭解更多資訊，請訪問或關注Biocartis的Twitter@Biocartis_、Facebook或LinkedIn。
Biocartis and Idylla are registered trademarks in Europe, the United States and other countries. The Biocartis and Idylla trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.
Biocartis和伊迪拉都是在歐洲、美國和其他國家註冊的商標。Biocartis和伊迪拉商標和徽標是Biocartis擁有的商標。請參考產品標籤，瞭解每種生物卡特斯產品的適用目標用途。
This press release is not for distribution, directly or indirectly, in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933, as amended.
本新聞稿不適用於在任何司法管轄區直接或間接分發，因為這樣做是非法的。任何閱讀本新聞稿的人都應瞭解並遵守任何此類限制。Biocartis對任何人違反任何此類限制不承擔任何責任。本新聞稿不構成在任何司法管轄區出售或購買證券的要約或邀請。如果沒有在美國證券交易委員會註冊或根據修訂後的1933年美國證券法獲得註冊豁免，Biocartis的證券不得在美利堅合眾國發行或出售。
Forward-looking statements
前瞻性陳述
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
本新聞稿中的某些陳述、信念和意見是前瞻性的，它們反映了公司或適當時公司董事或管理人員對未來事件的預期和預測，如公司的經營結果、財務狀況、流動性、業績、前景、增長、戰略和公司所處的行業。就其性質而言，前瞻性陳述涉及許多風險、不確定性、假設和其他因素，可能導致實際結果或事件與前瞻性陳述明示或暗示的結果或事件大相徑庭。這些風險、不確定性、假設和因素可能對本文所述計劃和事件的結果和財務影響產生不利影響。許多因素，包括但不限於需求、競爭和技術的變化，可能會導致實際事件、表現或結果與任何預期的發展大不相同。本新聞稿中包含的有關過去趨勢或活動的前瞻性陳述並不是對未來業績的保證，也不應被視為此類趨勢或活動將在未來繼續下去的表述。此外，即使實際結果或事態發展與本新聞稿中的前瞻性陳述一致，這些結果或事態發展也可能不代表未來的結果或事態發展。對於此類前瞻性陳述的準確性或公正性，不作任何陳述或保證。因此，公司明確表示不承擔任何義務或承諾因預期的任何變化或這些前瞻性陳述所基於的事件、條件、假設或情況的任何變化而發佈對本新聞稿中任何前瞻性陳述的任何更新或修訂，除非法律或法規明確要求這樣做。公司或其顧問或代表、其任何子公司或任何此類人士的高級管理人員或員工均不保證此類前瞻性陳述所依據的假設沒有錯誤，也不對本新聞稿中包含的前瞻性陳述的未來準確性或預測發展的實際發生承擔任何責任。您不應過分依賴前瞻性陳述，這些陳述僅反映了本新聞稿發佈之日的情況。
1 Representing Marcofin BV
1代表Marcofin BV
譯文內容由第三人軟體翻譯。